Benzinga | Jul 29, 2021 12:04PM EDT

Analyst Ratings For Sage Therapeutics

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months AgoBullish 0 1 1 0Somewhat Bullish 0 0 0 0Indifferent 0 0 4 0Somewhat Bearish 0 0 0 0Bearish 0 0 0 0

In the last 3 months, 7 analysts have offered 12-month price targets for Sage Therapeutics. The company has an average price target of $77.86 with a high of $96.00 and a low of $62.00.

This current average represents a 22.78% increase from the previous average price target of $100.83.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts can recommend "buy", "sell", "hold", or similar verbage for each stock based on that company's recent performance. "Buy" indicates that an analyst is optimistic about a stock's short-term or mid-term growth and is a recommendation to purchase the stock. On the other hand, "Sell" implies that an analyst forecasts a downwards trend for the stock. "Hold" suggests that investors should maintain their positions on that stock because of forecasted stagnation or lack of new information.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.